Regenerative Medicine Market Will Reach $4.8bn In 2015 According” Says New Visiongain Report

LONDON - Feb. 26, 2015 - PRLog -- LONDON, UK, 3^rd of February 2015: A new report by visiongain (http://www.visiongain.com/) calculates that the global translational regenerative medicine market will reach $4.8bn in 2015 with revenues showing growth to 2025. These revenue forecasts and others appear in visiongain’s latest report Translational Regenerative Medicine: Market Prospects 2015-2025. (https://www.visiongain.com/Report/1390/Translational-Regenerative-Medicine-Market-Prospects-2015-2025) Visiongain is a leading market intelligence company based in London, UK.

The translational regenerative medicine market (https://www.visiongain.com/Pharma/47/Reports) is experiencing a period of abundant opportunities for growth. There are an abundance of innovative technologies and products in regenerative medicine (RM) of which many are currently in late-stage development. As more clinical trials are conducted using these technologies more clinical data highlighting the efficacy of RM products will emerge; therefore easing the regulatory constraints on their usage. The market for regenerative medicine looks set for rapid growth over the next ten years and we predict that stem cell therapies will play a critical role in this expansion. Stem cell therapy products such as Osteocel Plus, Trinity Elite, and Prochymal will continue to grow their revenues as they gain new grounds and expand into new markets. Tissue engineering, which has so far found success mainly in wound care with Dermagraft and Apligraf, will be expanded into new indications and new geographical markets. Autologous chondrocyte implantation and the development of bio-artificial organs will also boost the market for tissue engineering.

Moses Akintomide-Akinwamide, a senior pharmaceutical and medical technology market analyst at Visiongain explains: “Following decades of scepticism and distrust surrounding them, regenerative medicine products appear to finally be gaining acceptance amongst the wider medical communities in Europe and North America. The development pipeline for the various segments of the market appears strong and we expect some of these products to make their way onto the market over the forecast period. Strong support from government entities coupled with the improvements to regulatory frameworks in which companies within the regenerative medicine market operate will contribute to the growth of the market. However, the lack of adequate venture capital funding, particularly for the small biotech companies that make up a large proportion of the TRM market may stunt innovation. The relatively high price currently being charged for most regenerative medicine products may also act to hinder their reimbursement by the increasingly cost-conscious payers”

Visiongain’s new report provides revenue forecasts to 2025 for the global translational regenerative medicine market and its leading regional markets. It forecasts sales in the US, Europe, Asia-Pacific, and the rest of the world. The report also forecasts sales for segments of the translational regenerative medicine market. These include stem cell therapies, tissue engineering, and gene therapies. Analysis and sales forecasts for key marketed products in each of these segments are provided together with profiles, analysis and sales forecasts of products in the development pipeline. The report also includes analysis of strengths, weaknesses, opportunities and threats to the market, as well as porter’s five force analyses examining the powers of suppliers and buyers, the threat of substitutes and new entrants, and the rivalry amongst competitors in the market. Transcripts of interviews with key opinion leaders in the industry sharing their views on current market trends and the unmet needs in the market are also included in the report.

Translational Regenerative Medicine: Market Prospects 2015-2025 adds to visiongain’s extensive range of analytical reports on industries and markets in healthcare.

For further information about this report please visithttps://www.visiongain.com/Report/1390/Translational-Regenerative-Medicine-Market-Prospects-2015-2025

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com

Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail tosara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.